Background: De novo metabolic syndrome (MS) is a frequent complication after liver transplantation (LT). The aim of this prospective study is to identify potential risk factors longitudinally associated to post-LT de novo MS. Patients without pre-LT MS who underwent LT between April 2013 and October 2017 were prospectively included. Metabolic variables were collected at LT and at 6, 12, and 24 months post-LT. Results: Sixty-three patients fulfilled the inclusion criteria (76% male, mean age 53.6±9.5 years). The prevalence of de novo MS was 46%, 43%, and 49% at 6, 12, and 24 months after LT, respectively. Among other MS components, the prevalence of type 2 diabetes, hypertension and hypertriglyceridemia significantly increased after LT. Cons...
Objective The incidence of metabolic syndrome (MS) increases after liver transplantation. This study...
Excessive weight gain, hypertension, hyperlipidaemia and diabetes are frequently observed in patient...
Liver transplant provides a definitive therapeutic measure for patients with chronic and acute liver...
BACKGROUND De novo metabolic syndrome (MS) is a frequent complication after liver transplantation...
The development of nutritional and metabolic abnormalities represents an important burden in patient...
Background: The metabolic syndrome is a common condition among liver transplanted patients and contr...
Metabolic syndrome (MS) is a cluster of metabolic derangements associated with insulin resistance an...
Abstract Metabolic syndrome (MS) is an established risk factor for atherosclerosis and cardiovascula...
Background: Liver transplant recipients are at increased risk of metabolic complications, including ...
Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ tran...
Post-liver transplant (LT) metabolic syndrome (PTMS) and cardiovascular (CVS) mortality are becoming...
Background/aims: Post-liver transplant (LT) metabolic syndrome (PTMS) and cardiovascular (CVS) morta...
Background: Post-liver transplant metabolic syndrome (PTMS) is a significant independent risk factor...
Objective Patients who have undergone transplantation often develop metabolic syndrome (MetS) and de...
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage l...
Objective The incidence of metabolic syndrome (MS) increases after liver transplantation. This study...
Excessive weight gain, hypertension, hyperlipidaemia and diabetes are frequently observed in patient...
Liver transplant provides a definitive therapeutic measure for patients with chronic and acute liver...
BACKGROUND De novo metabolic syndrome (MS) is a frequent complication after liver transplantation...
The development of nutritional and metabolic abnormalities represents an important burden in patient...
Background: The metabolic syndrome is a common condition among liver transplanted patients and contr...
Metabolic syndrome (MS) is a cluster of metabolic derangements associated with insulin resistance an...
Abstract Metabolic syndrome (MS) is an established risk factor for atherosclerosis and cardiovascula...
Background: Liver transplant recipients are at increased risk of metabolic complications, including ...
Cardiac and cerebral vascular diseases are leading causes of morbidity and death in solid organ tran...
Post-liver transplant (LT) metabolic syndrome (PTMS) and cardiovascular (CVS) mortality are becoming...
Background/aims: Post-liver transplant (LT) metabolic syndrome (PTMS) and cardiovascular (CVS) morta...
Background: Post-liver transplant metabolic syndrome (PTMS) is a significant independent risk factor...
Objective Patients who have undergone transplantation often develop metabolic syndrome (MetS) and de...
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage l...
Objective The incidence of metabolic syndrome (MS) increases after liver transplantation. This study...
Excessive weight gain, hypertension, hyperlipidaemia and diabetes are frequently observed in patient...
Liver transplant provides a definitive therapeutic measure for patients with chronic and acute liver...